New centers on therapeutics look at real-life drug use

Since 2000, there have been several types of warnings about the drug Remicade (infliximab), a biological therapeutic product indicated for rheumatoid arthritis and Crohn's disease. Tuberculosis and other opportunistic infections have been reported in clinical research and elsewhere. The manufacturer has warned that patients should be given a TB skin test, and that treatment for any latent TB infection should be started before infliximab use.

Related Videos
Dr. Charles Lee
© 2023 MJH Life Sciences

All rights reserved.